Sunshine Biopharma (SBFM) Notes Payables (2012 - 2021)

Sunshine Biopharma has reported Notes Payables for 10 years, with the latest figure at $1.9 million in Q4 2021.

• For the quarter ending Q4 2021, Notes Payables rose 1222.56% year-over-year to $1.9 million; the trailing twelve-month figure through Dec 2021 stood at $1.9 million (up 1222.56% YoY), and the FY2021 full-year result was $1.9 million, up 1222.56% from the prior year.
• Notes Payables for Q4 2021 stood at $1.9 million, up from $330000.0 in the prior quarter.
• The five-year high for Notes Payables was $1.9 million in Q4 2021, with the low at $11750.0 in Q3 2018.
• Historically, Notes Payables has averaged $344423.8 across 5 years, with a median of $191129.0 in 2017.
• Annual changes were most pronounced in 2018 — Notes Payables plunged 97.0% — and 2021, when it surged 1222.56%.
• Sunshine Biopharma's Notes Payables stood at $205742.0 in 2017, then increased by 18.15% to $243094.0 in 2018, then sank by 46.83% to $129261.0 in 2019, then rose by 11.14% to $143661.0 in 2020, then surged by 1222.56% to $1.9 million in 2021.
• The last three Notes Payables figures came in at $1.9 million (Q4 2021), $330000.0 (Q2 2021), and $143661.0 (Q1 2021), per Business Quant data.